Insilico Medicine partners with Master Investor
Insilico Medicine a biotechnology company specialising in the application of artificial intelligence for drug discovery, biomarker development, and ageing research has announced its second year of partnership with Master Investor at the annual Master Investor Show. The event will take place on Saturday, April 6th 2019 at the Business Design Centre, London. Around 5,000 private investors will gather in London, to meet nearly 100 CEOs of public companies and start-ups.
Insilico Medicine will host ‘The Lab’, a laboratory themed interactive experience room presenting Young AI – an AI-powered platform that enables users to manage their health, track changes over time and optimise their lifestyle. The company provides a range of consumer-facing applications using the advanced bioinformatics techniques and deep learning approaches.
Young.AI is an innovative platform that keeps track of ageing from the inside out. Consumers can upload their photograph or recent blood test and the system will assess and generate their biological, predicted age. The system makes it possible to track progress over time, to see how lifestyle factors affect biological age.
Alex Zhavoronkov Ph.D., Founder and CEO of Insilico Medicine, presented the latest advances in artificial intelligence for drug discovery and longevity biotechnology at Master Investor’s autumn longevity investment event and last year’s Master Investor Show. The presentation covered the applications of artificial intelligence transforming pharmaceutical industry R&D and accelerating the drug discovery process.
Insilico Medicine will this year be participating in the Main Stage panel discussion, ‘Investing in the Age of Longevity’ where they will be joined by fellow longevity expert, Aubrey de Grey and others to discuss the latest developments in longevity and the opportunities for investors.
Dr. Zhavoronkov is delighted to be returning to the event as a partner:
“We are very happy to present our work in ageing research and artificial intelligence at one of Europe’s largest investor shows. The topic of AI for Ageing research and Productive longevity is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area.”
Amanda Taylor, Master Investor’s Chief Commercial Officer said:
“We are excited to have Insilico Medicine hosting their laboratory themed experience at the show for the second year running. We hope the interactivity of ‘The Lab’ will showcase Insilico’s work in a way that educates and excites our attendees about the opportunity for investment in the longevity technologies.”
To meet Insilico at The Master Investor Show, sign up for your free ticket using code: LONGEVITY
About Master Investor Ltd.
Master Investor Ltd. is an investment media and events company that delivers independent, financial commentary and analysis to UK private investors and traders. The annual Master Investor Show introduces its 5000+ private investor audience to companies they can invest into. It offers clients opportunities to generate leads to an audience with significant investable funds.
Master Investor Ltd. is backed by visionary entrepreneur, Jim Mellon, amongst the top 10% in the Sunday Times Rich List.
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, USA, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and ageing research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and ageing. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8.